# A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

> **NCT03184870** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 332 (actual)

## Conditions studied

- Colorectal Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** BMS-813160
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** 5-fluorouracil (5-FU)
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03184870
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-08
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-06-14
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184870, "A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03184870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*